CRNX News and Press, Crinetics Pharmaceuticals Inc. From 11/16/20

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announce...

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announc...

Crinetics Pharmaceuticals (CRNX): Q3 GAAP EPS of -$0.56 misses by $0.03.Cash, cash equivalents and investments of $186.8M.Press Release For further details see: Crinetics Pharmaceuticals EPS misses by $0.03

Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trial s of oral paltusotine for the treatment of acromegaly CRN04777 received Rare Pediatric Disease Designation for the treatment of congenital hyperinsulin...

A Phase 2 clinical trial, ACROBAT Edge, evaluating Crinetics Pharmaceuticals' (CRNX) lead candidate paltusotine (formerly CRN00808) for the treatment of acromegaly met the primary endpoint. Specifically, once-daily oral doses of paltusotine maintained insulin-like growth factor-1 (IGF-1) leve...

ACROBAT Edge Results Showed Maintenance of IGF-1 Suppression with Paltusotine After Switching from Depot Somatostatin Receptor Ligand Monotherapy Paltusotine was observed to be well tolerated among the 60 participants in the ACROBAT Edge and Evolve Studies On Track to In...

Spruce Biosciences has filed to raise $75 million in an IPO. The firm is developing treatments for rare endocrine disorders. Early trial results have been impressive and the IPO appears reasonably priced, so is worth a look for long-term hold life science investors. For furt...

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced t...

Crinetics Pharmaceuticals (NASDAQ: CRNX ) announces that a presentation of its orally available small molecule adrenocorticotropic hormone (ACTH) antagonist was selected for a late-breaking session a the virtual European Congress of Endocrinology on September 8. More news on: Crinetics...

SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced t...